News Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN Forms Unprecedented Advisory Board of Digital Thought-Leaders to Advance Commercial Plans

CHAPEL HILL, N.C., Jul 19, 2011 (BUSINESS WIRE) --

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, today announced the formation of the POZEN Digital Advisory Board. POZEN has assembled an esteemed group of digital thought-leaders both in and outside of healthcare to help progress the Company's vision for revolutionizing the traditional pharmaceutical commercial model. Through both the Company's unique clinical development and marketing approach, POZEN aims to bring lifesaving drugs to market more affordably than current models allow. The Digital Advisory Board will work alongside the Company as it prepares to launch and market its first products - including PA32540, being investigated for the secondary prevention of cardiovascular and cerebrovascular disease - and will advise POZEN on the use of digital technology to more effectively and efficiently engage and communicate with customers.

"The pharmaceutical industry has only begun to scratch the surface of employing digitally-based commercialization approaches. As POZEN moves forward to commercialize its PA pipeline, our goal in collaborating with these advisors is to look beyond the industry to identify untapped digital strategies that will help us deliver an affordable and accessible product to our customers," said Liz Cermak, Executive Vice President and Chief Commercial Officer of POZEN. "POZEN feels privileged to be working with such accomplished and forward-looking individuals whose expertise and insights will help to shape our plans that will ultimately solidify our position as innovators."

The POZEN Digital Advisory Board is comprised of leaders in technology, social media and digital marketing, bringing expertise and insights from a wide range of industries to POZEN. Any views or opinions expressed by the advisors as part of the Digital Advisory Board are their own and not those of their employers. The POZEN Digital Advisory Board includes:

  • Raj Amin, Chief Executive Officer and Co-Founder, HealthiNation; previously Vice President of Business Development, N2 Broadband
  • John Bax, Chief Financial Officer, LivingSocial; previously Chief Financial Officer, RecycleBank and Walmart.com
  • Bonin Bough, Director of Digital and Social Media, PepsiCo; previously Director of Global Interactive, Social and Emerging Media Practice, Weber Shandwick
  • Marc Monseau, Founder and Principal, MDM Communication, LLC; previously Director of Corporate Communication and Social Media, Johnson & Johnson
  • Daniel Palestrant, M.D., Chief Executive Officer and Founder, Sermo; previously Founder, Azygos, Inc.
  • Meredith Ressi, President, Manhattan Research; previously Chief Operating Officer, Integrated Wellness Solutions

The advisors will be participating in a media briefing and roundtable discussion on the topic of advancing the pharma model through lessons in digital later this year. Additional details will be forthcoming.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained U.S. Food and Drug Administration (FDA) approval of two self-invented products in two years - something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. The lead candidate PA32540 is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

About PA

POZEN is creating a portfolio of integrated aspirin therapies - the PA product platform. The products in the PA portfolio are intended to significantly reduce GI ulcers and other GI complications compared to taking aspirin alone.

The first candidate is PA32540. It is a coordinated-delivery tablet combining immediate-release omeprazole, a proton pump inhibitor, layered around pH-sensitive aspirin. This novel, patented product is administered orally once a day and will be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers. POZEN has completed enrollment for the long-term safety study and continues enrollment on the two pivotal studies, targeting a New Drug Application filing in 2012.

Additionally, POZEN is conducting exploratory work on integrated aspirin therapies for other pain and pain-related conditions.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on GlaxoSmithKline for the sales and marketing of Treximet(R) and our dependence on AstraZeneca for the sales and marketing of VIMOVO(TM); competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2011. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

SOURCE: POZEN

POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
or
Stephanie Bonestell, 919-913-1030
Manager, Investor Relations & Public Relations

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.